CD8A and neoplasm: XCR1 expressed by cross-presenting DCs plays a role, as it is known that XCR1 engagement by its ligand, XCL1, promotes the interaction between cross-presenting DC and CD8+ T cells to enhance the tumor immunity of immune system [56,57].